Stock CDTX CIDARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
11.81 USD -1.42% Intraday chart for Cidara Therapeutics, Inc. -3.91% -25.63%
25/04 Top Premarket Gainers MT
25/04 North American Morning Briefing : More Tech -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
Cidara Therapeutics, Inc. Announces Janssen?S Election to Proceed Under Its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development
Cidara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cidara Therapeutics Says Partner Melinta Therapeutics Launched Candidemia Treatment Rezzayo in US
Cidara Therapeutics Provides Update on REZZAYO? (Rezafungin for Injection)
Cidara Therapeutics Says US FDA Grants Fast Track Designation to Influenza Drug Candidate
Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CDTX Stock
  4. News Cidara Therapeutics, Inc.
  5. Other languages